Skip to content

To investigate the effect of pancreatin on diarrhea of crohn's disease patients taking total enteral nutrition

To investigate the effect of pancreatin on diarrhea of crohn's disease patients taking total enteral nutrition

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200058343
Enrollment
Unknown
Registered
2022-04-07
Start date
2022-04-13
Completion date
Unknown
Last updated
2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn's disease

Interventions

Experimental group:Take trypsin medications

Sponsors

Renmin Hospital of Wuhan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-75 years; 2. According to the diagnosis of CD recommended in the Consensus Opinion on the Diagnosis and Treatment of Inflammatory Bowel Disease (imaging, endoscopic and biopsy features, clinical manifestations), the diagnosis of CD was confirmed; 3. Serum C-reactive protein (CRP) >=10mg/L and Crohn's disease activity index (CDAI) > 150 and 3; 5. Symptoms of diarrhea after receiving total enteral nutrition treatment; 6. Agree to participate in the study.

Exclusion criteria

Exclusion criteria: 1. Symptoms of intestinal obstruction; 2. Surgical history within the last 6 months; 3. Suffer from metabolic diseases such as diabetes; 4. Have received EN treatment within the last 6 months.

Design outcomes

Primary

MeasureTime frame
Diarrhea remission rate;

Secondary

MeasureTime frame
Severity of illness;Nutritional status of patients;Relationship between diarrhea change and medication frequency;Changes in patient compliance;Relationship between improvement of diarrhea and compliance;Changes in fecal flora of patients;

Countries

China

Contacts

Public ContactAn Ping
anping_05@163.com+86 18627068700

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026